Magrolimab plus azacitidine results in promising activity in higher-risk MDS patients
Myelodysplastic syndromes (MDS) are a diverse group of bone marrow disorders in which immature stem cells do not mature to become red blood cells, white blood cells or platelets. Patients with higher-risk MDS tend to have ...
Mar 9, 2023
0
19